Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2018

01.08.2018 | Research Article

Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone

verfasst von: Jun-Hong Ye, Yunn-Fang Ho, Angela W.-F. On, Wen-Wen Chen, Yen-Ming Huang, Wei-I. Huang, Yun-Wen Tang

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background A pharmacovigilance database of real-world adverse drug reaction (ADR) reports is helpful for characterising adverse events and identifying new signals after drug approval. Objective This study aimed to analyse trends of ADR reporting in relation to liver injury and to delineate critical factors for suspected drug-related hepatotoxicity with a focus on reports associated with amiodarone. Setting The 2000–2014 Taiwan pharmacovigilance database. Method Relevant Standardized Medical Dictionary for Regulatory Activities queries were used to identify reports associated with liver injury. Information on ADR, patient characteristics, and the verbatim pertaining to amiodarone prescriptions, liver injury, comedications, and comorbidities were extracted and evaluated. Group comparisons between Hy’s Law cases and Temple’s Corollary cases of suspected amiodarone-related hepatotoxicity were performed. Main outcome measure Number and nature of drug-related liver injuries, particularly those associated with amiodarone. Results Of the 98,777 ADR reports over a 15-year period, 4261 (4.3%) were related to liver injury. Sixty-eight reports contained amiodarone prescriptions, but only 49 (1.1%) were eligible for further analysis. Hepatotoxic cases associated with amiodarone mostly occurred within 1 week, exhibited a hepatocellular pattern, and were more common among elderly individuals. Among 23 discernible cases, four (17.4%) recovered fully from liver injury. The critical Hy’s Law cases were associated with shorter height, lower body surface area, and higher average daily doses. Conclusion This study substantiates the importance of ADR reporting. Data pertaining to drug-associated liver injury and factors associated with suspected amiodarone-related hepatotoxicity warrants continual attention in pharmacovigilance for those at risk, especially the elderly.
Literatur
1.
Zurück zum Zitat Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989;46(5):929–44.PubMed Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989;46(5):929–44.PubMed
2.
Zurück zum Zitat Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324(6):370–6.CrossRef Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324(6):370–6.CrossRef
3.
Zurück zum Zitat Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.CrossRef Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.CrossRef
4.
Zurück zum Zitat Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.CrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.CrossRef
5.
Zurück zum Zitat Middleton RK. Adverse drug reactions. In: Allen LV, editor. Remington: the science and practice of pharmacy, vol. 2. 21st ed. London: Pharmaceutical Press; 2013. p. 2013–22. Middleton RK. Adverse drug reactions. In: Allen LV, editor. Remington: the science and practice of pharmacy, vol. 2. 21st ed. London: Pharmaceutical Press; 2013. p. 2013–22.
6.
Zurück zum Zitat Vlahović-Palčevski V, Mentzer D. Postmarketing surveillance. Handb Exp Pharmacol. 2011;205:339–51.CrossRef Vlahović-Palčevski V, Mentzer D. Postmarketing surveillance. Handb Exp Pharmacol. 2011;205:339–51.CrossRef
7.
Zurück zum Zitat Bahri P, Arlett P. Regulatory pharmacovigilance in the European Union. In: Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014. p. 173–84. Bahri P, Arlett P. Regulatory pharmacovigilance in the European Union. In: Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014. p. 173–84.
8.
Zurück zum Zitat Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014. Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014.
10.
Zurück zum Zitat On AW-F, Chih LH, Liu C, Lin KH, Huang YW, Tai HY, et al. A unique drug-injury relief system in Taiwan: comparing drug-injury compensation in different countries. J Pharm Health Serv Res. 2012;3(1):3–9.CrossRef On AW-F, Chih LH, Liu C, Lin KH, Huang YW, Tai HY, et al. A unique drug-injury relief system in Taiwan: comparing drug-injury compensation in different countries. J Pharm Health Serv Res. 2012;3(1):3–9.CrossRef
11.
Zurück zum Zitat Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–34.CrossRef Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–34.CrossRef
12.
Zurück zum Zitat Licata A. Adverse drug reactions and organ damage: the liver. Eur J Intern Med. 2016;28:9–16.CrossRef Licata A. Adverse drug reactions and organ damage: the liver. Eur J Intern Med. 2016;28:9–16.CrossRef
13.
Zurück zum Zitat Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13(12):2173-89.e8.CrossRef Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13(12):2173-89.e8.CrossRef
14.
Zurück zum Zitat Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9–17.CrossRef Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9–17.CrossRef
15.
Zurück zum Zitat Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243–52.CrossRef Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243–52.CrossRef
16.
Zurück zum Zitat Temple R. Hy’s Law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–3.CrossRef Temple R. Hy’s Law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–3.CrossRef
17.
Zurück zum Zitat Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, et al. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy’s Law. Drug Saf. 2014;37(1):43–51.CrossRef Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, et al. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy’s Law. Drug Saf. 2014;37(1):43–51.CrossRef
18.
Zurück zum Zitat Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–96.CrossRef Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–96.CrossRef
21.
Zurück zum Zitat Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38(1):33–8.CrossRef Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38(1):33–8.CrossRef
22.
Zurück zum Zitat Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191–8.CrossRef Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191–8.CrossRef
23.
Zurück zum Zitat Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.PubMedPubMedCentral Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.PubMedPubMedCentral
24.
Zurück zum Zitat Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Capitanio N, Tamborra R, Romano AD, Quinto M, Blonda M, Vendemiale G, Altomare E. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med. 2011;51(12):2234–42.CrossRef Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Capitanio N, Tamborra R, Romano AD, Quinto M, Blonda M, Vendemiale G, Altomare E. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med. 2011;51(12):2234–42.CrossRef
25.
Zurück zum Zitat Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012;125(1):126–33.CrossRef Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012;125(1):126–33.CrossRef
26.
Zurück zum Zitat Chao P-H, Huang C-Y, Chen W-W. An analysis on 2015 post-marketing spontaneous reports of adverse drug reactions. Drug Saf Newsl. 2016;53:10–8 (in Chinese). Chao P-H, Huang C-Y, Chen W-W. An analysis on 2015 post-marketing spontaneous reports of adverse drug reactions. Drug Saf Newsl. 2016;53:10–8 (in Chinese).
29.
Zurück zum Zitat International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 18.0. https://www.meddra.org/software-packages, 2015. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 18.0. https://​www.​meddra.​org/​software-packages, 2015.
30.
Zurück zum Zitat Iasella CJ, Johnson HJ, Dunn MA. Adverse drug reactions: type A (intrinsic) or type B (idiosyncratic). Clin Liver Dis. 2017;21(1):73–87.CrossRef Iasella CJ, Johnson HJ, Dunn MA. Adverse drug reactions: type A (intrinsic) or type B (idiosyncratic). Clin Liver Dis. 2017;21(1):73–87.CrossRef
32.
Zurück zum Zitat Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66.CrossRef Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66.CrossRef
33.
Zurück zum Zitat Thomson Reuters Healthcare. Micromedex computerized clinical information system. Micromedex website, 2015. micromedex.com. Accessed 5 Aug 2015. Thomson Reuters Healthcare. Micromedex computerized clinical information system. Micromedex website, 2015. micromedex.com. Accessed 5 Aug 2015.
35.
Zurück zum Zitat Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14.CrossRef Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14.CrossRef
36.
Zurück zum Zitat Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–22.CrossRef Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–22.CrossRef
37.
Zurück zum Zitat Robles-Díaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267.CrossRef Robles-Díaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267.CrossRef
38.
Zurück zum Zitat Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23(7):1215–22.CrossRef Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23(7):1215–22.CrossRef
39.
Zurück zum Zitat Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15–16):697–703.CrossRef Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15–16):697–703.CrossRef
41.
Zurück zum Zitat Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147(1):20–4.CrossRef Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147(1):20–4.CrossRef
42.
Zurück zum Zitat Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679–85.CrossRef Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679–85.CrossRef
43.
Zurück zum Zitat Zimmerman HJ. Drugs used in cardiovascular disease. In: Zimmerman HJ, editor. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 639–71. Zimmerman HJ. Drugs used in cardiovascular disease. In: Zimmerman HJ, editor. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 639–71.
44.
Zurück zum Zitat Rizzioli E, Incasa E, Gamberini S, Savelli S, Zangirolami A, Tampieri M. Acute toxic hepatitis after amiodarone intravenous loading. Am J Emerg Med. 2007;25(9):1082.e1-4.CrossRef Rizzioli E, Incasa E, Gamberini S, Savelli S, Zangirolami A, Tampieri M. Acute toxic hepatitis after amiodarone intravenous loading. Am J Emerg Med. 2007;25(9):1082.e1-4.CrossRef
45.
Zurück zum Zitat Verhovez A, Elia F, Riva A, Ferrari G, Aprà F. Acute liver injury after intravenous amiodarone: a case report. Am J Emerg Med. 2011;29(7):843.e5-6.CrossRef Verhovez A, Elia F, Riva A, Ferrari G, Aprà F. Acute liver injury after intravenous amiodarone: a case report. Am J Emerg Med. 2011;29(7):843.e5-6.CrossRef
46.
Zurück zum Zitat Pirovino M, Müller O, Zysset T, Honegger U. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology. 1988;8(3):591–8.CrossRef Pirovino M, Müller O, Zysset T, Honegger U. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology. 1988;8(3):591–8.CrossRef
47.
Zurück zum Zitat Farrell GC. Drug-induced steatohepatitis. In: Farrell GD, editor. Drug-induced liver disease. Edinburge: Churchill Livingstone; 1994. p. 431–8. Farrell GC. Drug-induced steatohepatitis. In: Farrell GD, editor. Drug-induced liver disease. Edinburge: Churchill Livingstone; 1994. p. 431–8.
48.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRef Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRef
49.
Zurück zum Zitat Thiessard F, Roux E, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986–2001). Drug Saf. 2005;28(8):731–40.CrossRef Thiessard F, Roux E, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986–2001). Drug Saf. 2005;28(8):731–40.CrossRef
Metadaten
Titel
Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone
verfasst von
Jun-Hong Ye
Yunn-Fang Ho
Angela W.-F. On
Wen-Wen Chen
Yen-Ming Huang
Wei-I. Huang
Yun-Wen Tang
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2018
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0698-5

Weitere Artikel der Ausgabe 4/2018

International Journal of Clinical Pharmacy 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.